AstraZeneca is to sell European rights to its cholesterol drug Crestor (rosuvastatin) to Germany’s Grunenthal. Crestor is a statin and at its peak generated annual revenues of more than $7 ...

Obicetrapib monotherapy significantly improved the lipid profile of patients with heterozygous familial hypercholesterolemia ...

AstraZeneca Plc’s Chief Executive Officer ... including data from its experimental cholesterol drug that significantly reduced “bad” cholesterol in a mid-stage trial. That could be part ...

AstraZeneca has bought rights to an orally-active drug that inhibits PCSK9, offering a patient-friendly alternative to current cholesterol-lowering therapies that have to be delivered via a needle.

AstraZeneca CEO Pascal Soriot discusses earnings ... UN aviation council rules The six worst foods for your cholesterol UnitedHealth Group CEO Andrew Witty steps down, company suspends annual ...

A designer has created a concept car capable of driving on both water and land. Imagined by Bernardo Pereira, a student at ...

They have a cholesterol level above 70 ... is it fair to say that under all contemplated scenarios and in light of AstraZeneca's actions over the next two to three years, tariffs are not material ...

COPD cases are rising in women. Uncover the latest insights to enhance diagnosis and treatment in your women patients.

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

today announced the appointment of Adele Gulfo as an independent AstraZeneca said Monday its experimental pill lowered "bad" LDL cholesterol by 51%. But AstraZeneca stock fell in line with pharma ...